PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

计划入组 15 人 · 首次发布于 2023 年 10 月 2 日

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

计划入组 17 人 · 首次发布于 2024 年 4 月 16 日

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

计划入组 13 人 · 首次发布于 2024 年 5 月 14 日

MST-0300

Fc-MST-HN

Sobuzoxane

01 Communique Laboratory Inc

Canada

Miragen Therapeutics, Inc.

Renovaro

United States

Miist Therapeutics Secures $7M Seed Funding for Ultra-Rapid Inhaled Drug Delivery Platform

Mestag Therapeutics to Present Novel LTBR Agonist MST-0312 Data at Cancer Immunotherapy Symposium

Novel Magnetic Seizure Therapy Shows Promise for Depression Treatment with Fewer Cognitive Side Effects